Top Qs
Timeline
Chat
Perspective
Ga-68-Trivehexin
Contrast agent for cancer imaging From Wikipedia, the free encyclopedia
Remove ads
68Ga-Trivehexin[1] is a radiotracer for positron emission tomography (PET), obtained by labeling the peptide conjugate Trivehexin[1] with the positron emitting radionuclide gallium-68 (68Ga). 68Ga-Trivehexin targets (i.e., binds to) the cell surface receptor αvβ6-integrin and accumulates in αvβ6-integrin-abundant tissues after intravenous (i.v.) application. 68Ga-Trivehexin is thus applied for PET imaging of medical conditions associated with elevated αvβ6-integrin expression.
αvβ6-Integrin, the biological target of 68Ga-Trivehexin, is a heterodimeric transmembrane cell adhesion receptor whose primary natural ligand is latency associated peptide (LAP)[2] in its complex with transforming growth factor beta 1 (TGF-β1).[3][4] Binding of αvβ6-integrin to LAP releases[5] and thus, activates[6] TGF-β1. In early-stage cancer, TGF-β1 acts as a tumor suppressor[7] but can turn into a tumor promoter as cancers develop,[8][9][10] and furthermore induces fibrosis,[11][12] particularly of the lung.[13] As the likely most important activator of TGF-β1,[4] αvβ6-integrin is often found overexpressed in tumors[14] and fibrosis,[15] which is why 68Ga-Trivehexin PET imaging is primarily relevant in this medical context.
Remove ads
Chemistry
Summarize
Perspective
Trivehexin precursor
Like most precursors used for radiolabeling with radioactive metal cations, Trivehexin is composed of a dedicated complex ligand (a so-called chelator) for kinetically inert binding of the 68GaIII ion, and the bioligand(s) for binding to αvβ6-integrin. The chelator comprised in Trivehexin is a triazacycloalkane with 3 phosphinic acid substituents, with the basic structure 1,4,7-triazacyclononane-1,4,7-triphosphinate[16] (frequently abbreviated TRAP).[17][18][19] The αvβ6-integrin binding molecular unit is a cyclic nonapeptide with the amino acid sequence cyclo(YRGDLAYp(NMe)K).[1]
In the Trivehexin molecule, three of these cyclopeptides are attached by covalent bonds to a single TRAP chelator core. Since TRAP possesses three equivalent carboxylic acids for conjugation of other molecular units via amide formation, Trivehexin is a C3-symmetrical molecule with its three peptide bioligands being fully equivalent. The peptides are attached to the chelator core via the terminal amine group of the side chains of N-methyl lysine. Actually, the conjugation is not done by amide bonding directly, but involves prior functionalization of the peptide with a short molecular extension (a linker) bearing a terminal alkyne, and of TRAP with three linkers bearing terminal azides.[19] These components are assembled by means of copper(I) catalyzed alkyne-azide cycloaddition (CuAAC, also known as Huisgen reaction, a Click chemistry reaction), giving rise to the three 1,3-triazole linkages in the 68Ga-Trivehexin structure.[1]
Trivehexin is manufactured and distributed by the German company TRIMT GmbH.[20]
68Ga radiolabeling
68Ga-Trivehexin is a radioactive drug. The radioactive atom, gallium-68 (68Ga), decays with a half-life of approximately 68 min to the stable isotope zinc-68 (68Zn), to 89% by β+ decay whereby a positron with a maximum kinetic energy of 1.9 MeV is emitted (the remaining 11% are EC decays). Due to the short half-life, 68Ga-Trivehexin can not be manufactured long before use but the 68Ga has to be introduced into the molecule shortly before application. This process is referred to as radiolabeling, and is done by complexation of the trivalent cation 68GaIII by the TRAP chelator in Trivehexin.
68GaIII is usually obtained from a dedicated mobile radionuclide source, a Gallium-68 generator, in form of a solution in dilute (0.04–0.1 M) hydrochloric acid (frequently and imprecisely referred to as "68Ga chloride solution in HCl" despite it contains no species with a Ga–Cl bond but [68Ga(H2O)6]3+ complex hydrate cations).[21] For radiolabeling, the pH of the 68Ga containing generator eluate has to be raised from its initial value (depending on HCl concentration, pH 1–1.5) to pH 2–3.5 [22] using suitable buffers, such as sodium acetate. Then, Trivehexin (5–10 nmol) is added to the buffered 68Ga-containing solution, and the mixture is briefly heated to 50–100 °C (usually 2–3 min) to finalize the complexation reaction.[1][22]
Remove ads
Use as medical imaging agent
Summarize
Perspective
αvβ6-Integrin target
The abundance of αvβ6-integrin on most adult human cell types and respective tissues is low. It is however overexpressed in the context of several medical conditions, such as cancer[14] or fibrosis,[15] particularly idiopathic pulmonary fibrosis.[23]
In line with the finding that αvβ6-integrin is expressed by epithelial cells,[24] an elevated density of the protein is observed on the cell surfaces of many carcinomas (synonymous to cancers of epithelial origin).[14][25] Hence, 68Ga-Trivehexin can be used for PET imaging of αvβ6-integrin positive cancers (i.e., those whose cells possess a sufficiently high density of αvβ6 on their surface), including but not limited to pancreatic ductal adenocarcinoma,[26] non-small cell lung cancer, squamous cell carcinomas (SCC) of different origin (most notably, oral and esophageal SCC), as well as breast, ovarian, and bladder cancer. In colorectal cancer, expression of αvβ6-integrin is higher in the more aggressive forms and correlated with reduced overall survival.[27]
68Ga-Trivehexin has a high binding affinity to αvβ6-integrin (IC50 = 0.047 nM). Its affinity to other RGD-binding integrins is much lower (IC50 for αvβ3, αvβ8, and α5β1 are 2.7, 6.2, and 22 nM, respectively; note that for IC50, higher values mean lower affinity),[1] resulting in a high selectivity for αvβ6-integrin.
Imaging procedure
Since 68Ga is a positron emitter, 68Ga-Trivehexin is applicable for PET imaging. However, PET is rarely used as a standalone imaging technique these days. Most clinics use PET/CT or even PET/MRI systems that acquire morphological and functional images in a single workflow and thus, provide more detailed and useful medical information to the physician.
For clinical PET/CT diagnostics, an activity in the range of 80–150 MBq 68Ga-Trivehexin is injected intravenously (i.v.).[28][29] The tracer then distributes with the blood flow and moves into tissues by diffusion, where it specifically binds to its target αvβ6-integrin, while an excess is excreted via the kidneys and the urine. As a result, 68Ga-Trivehexin and, therefore, the positron-emitting radionuclide 68Ga, is preferably accumulated by αvβ6-integrin abundant tissues (for example, tumor tissue). Next, a PET/CT scanner is used to detect the gamma radiation which is generated by the annihilation of the positrons emitted by 68Ga (not the actual positrons, which do not leave the body but travel only a few millimetres through the tissue). The spatial distribution of the annihilation events is reconstructed from the raw detector data (referred to as listmode data), which eventually delivers a 3-dimensional data set of radioactivity distribution in the body. These data allow the visualization of αvβ6-integrin positive tissues as 2-dimensional tomographic images or 3-dimensional volume rendering. Typically, the PET/CT imaging is performed 45–60 minutes after the i.v. administration of 68Ga-Trivehexin.[29]
Cancers imaging
68Ga-Trivehexin has not yet obtained a marketing approval. It is used for clinical imaging of αvβ6-integrin expression in experimental settings.
Pancreatic cancer
First-in-human application of different αvβ6-integrin radiotracers has demonstrated that 68Ga-Trivehexin performed especially well in detecting pancreatic cancer, showing high uptake in tumor lesions and low background in the gastrointestinal tract (GI tract) (see image).[30] Since its introduction,[1] 68Ga-Trivehexin has been used predominantly for PET/CT imaging of pancreatic ductal adenocarcinoma (PDAC), for example, in single cases [28][31] and two cohorts (12 and 44 patients, respectively) [32][29] of suspected or known PDAC.
Breast cancer
The feasibility of 68Ga-Trivehexin PET imaging of breast cancer (BC) was demonstrated in a case of triple-negative BC.[33] Another report suggested that 68Ga-Trivehexin PET/CT might offer superior detection efficacy for breast cancer compared to 18F-FDG PET/CT.[34] Furthermore, in progesterone- and estrogen-receptor negative BC with elevated Ki67 proliferation index and strong E-cadherin, 68Ga-Trivehexin PET identified several 18F-FDG-avid lymph nodes as false positives.[35] In a patient with lobular BC and pancreatic neuroendocrine tumor (PNET), 68Ga-Trivehexin selectively showed a PET signal only in the lobular carcinoma, while the metabolic tracer 18F-FGD and the neuroendocrine tumor tracer 68Ga-DOTATATE yielded PET signals for both the BC and PNET lesions.[36]
Head-and-neck cancer
In a cohort of 20 suspected (19 confirmed) head-and-neck squamous cell carcinoma (HNSCC) cases, 68Ga-Trivehexin PET had a higher sensitivity (92.5%), positive predictive value (PPV, 100%), and accuracy (93%) than the standard 18F-FDG PET, for which sensitivity, PPV, and accuracy were 90%, 93.1%, and 84.3%, respectively.[32] 68Ga-Trivehexin was furthermore applied in a case of tonsillar carcinoma metastasized to the brain (see image).[31]
Other cancers
68Ga-Trivehexin was also applied in cases of bronchial mucoepidermoid carcinoma,[37] mucinous lung adenocarcinoma,[38] recurrent parathyroid carcinoma,[39] and papillary thyroid carcinoma.[40]
Imaging of benign and non-oncological conditions
Parathyroid adenoma (PTA)
In the context of primary hyperparathyroidism (PHPT), 68Ga-Trivehexin PET/CT was successfully applied for PET imaging of disseminated parathyroid adenoma with a detection rate of 94.1%,[41] and furthermore for delineation of osteolysis-associated brown tumors which occur as a result of persistent hyperparathyroidism.[42]
Fibrosis
In accordance with the known expression of αvβ6-integrin in early lung fibrosis,[13] 68Ga-Trivehexin was used for PET/CT imaging of idiopathic pulmonary fibrosis (IPF).[43] In explorative studies, 68Ga-Trivehexin could generate an IPF-specific PET signal while the same tissue areas were PET-negative using the standard metabolic PET tracer 18F-FDG.[38][44] 68Ga-Trivehexin PET scans displayed an uptake of SUVmax = 5.53 in fibrotic lung areas and thus enabled clear differentiation of fibrotic from non-fibrotic lung tissue.[38]
Safety
Like for other radioactive imaging agents in medicine, the applied amounts of radioactivity are so low that radiation-related adverse effects are very unlikely to occur, and have not been observed in practice. Consistent with the "tracer principle", the amount of pharmacologically active compound injected to a patient in the course of such an examination is extremely low. Adverse events, such as toxicity or allergic reactions, are thus highly improbable. No adverse or clinically detectable pharmacologic effects were observed following intravenous administration of 68Ga-Trivehexin when administered to cancer patients, and there were no significant changes in vital signs, laboratory study results, or electrocardiograms.[29] In a study involving healthy volunteers, researchers again reported no adverse or clinically detectable pharmacologic effects and no significant changes in vital signs.[22]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads